The Current Ratio as of December 2024 (TTM) for Regeneron Pharmaceuticals, Inc. (REGN) is 5.28

According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.28. This represents a change of -2.56% compared to the average of 5.42 of the last 4 quarters.

Regeneron Pharmaceuticals, Inc. (REGN) Historical Current Ratio (quarterly & annually)

How has REGN Current Ratio performed in the past?

The mean historical Current Ratio of Regeneron Pharmaceuticals, Inc. over the last ten years is 5.20. The current 5.28 Current Ratio has changed 10.06% with respect to the historical average. Over the past ten years (40 quarters), REGN's Current Ratio was at its highest in in the June 2018 quarter at 6.48. The Current Ratio was at its lowest in in the June 2020 quarter at 2.12.

Regeneron Pharmaceuticals, Inc. (REGN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Regeneron Pharmaceuticals, Inc. (REGN) Average Current Ratio

How has REGN Current Ratio performed in the past?

The current Current Ratio of Regeneron Pharmaceuticals, Inc. (REGN) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Regeneron Pharmaceuticals, Inc. (REGN) Current Ratio vs. Peers

How is REGN’s Current Ratio compared to its peers?

Regeneron Pharmaceuticals, Inc.’s Current Ratio is less than CRISPR Therapeutics AG (21.64), greater than Novo Nordisk A/S (0.94), greater than Sarepta Therapeutics, Inc. (3.84), less than Intellia Therapeutics, Inc. (6.73), greater than Incyte Corporation (1.87), greater than Alnylam Pharmaceuticals, Inc. (2.75), greater than United Therapeutics Corporation (4.58), greater than Ultragenyx Pharmaceutical Inc. (2.81), greater than Apellis Pharmaceuticals, Inc. (4.36), greater than PTC Therapeutics, Inc. (2.10), less than Reata Pharmaceuticals, Inc. (6.75), greater than Intercept Pharmaceuticals, Inc. (4.22), less than Krystal Biotech, Inc. (7.97), less than Madrigal Pharmaceuticals, Inc. (5.98), greater than BeiGene, Ltd. (1.93), greater than BioMarin Pharmaceutical Inc. (4.27), less than ImmunoGen, Inc. (5.47), less than Prometheus Biosciences, Inc. (31.04), less than Arrowhead Pharmaceuticals, Inc. (6.74), less than Ionis Pharmaceuticals, Inc. (8.91),

Build a custom stock screener for Regeneron Pharmaceuticals, Inc. (REGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Regeneron Pharmaceuticals, Inc. (REGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.